855 Montgomery St
Fort Worth TX 76107
Medical School: Umdnj New Jersey School Of Osteo Medicine - 1996
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: Yes
Taxonomy Codes:204D00000X 207Q00000X
Request Appointment Information
Awards & Recognitions
Dr. David Mason is associated with these group practices
|HCPCS Code||Description||Average Price||Average Price
Allowed By Medicare
|HCPCS Code:98928||Description:Osteopathic manipulation||Average Price:$155.25||Average Price Allowed
|HCPCS Code:99214||Description:Office/outpatient visit est||Average Price:$187.00||Average Price Allowed
|HCPCS Code:98927||Description:Osteopathic manipulation||Average Price:$131.63||Average Price Allowed
|HCPCS Code:98926||Description:Osteopathic manipulation||Average Price:$101.81||Average Price Allowed
|HCPCS Code:99213||Description:Office/outpatient visit est||Average Price:$115.96||Average Price Allowed
HCPCS Code Definitions
- Osteopathic manipulative treatment (OMT); 3-4 body regions involved
- Osteopathic manipulative treatment (OMT); 5-6 body regions involved
- Osteopathic manipulative treatment (OMT); 7-8 body regions involved
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
Medical Malpractice Cases
Medical Board Sanctions
Osteopathic Manipulative Medicine
*These referrals represent the top 10 that Dr. Mason has made to other doctors
Expanding the donor pool: donation after cardiac death. - Thoracic surgery clinics
Lung transplantation (LTx) is the definitive treatment of patients with end-stage lung disease. Availability of donor lungs remains the primary limitation and leads to substantial wait-list mortality. Efforts to expand the donor pool have included a resurgence of interest in the use of donation after cardiac death (DCD) lungs. Unique in its physiology, lung viability seems more tolerant to the variable durations of ischemia that occur in DCD donors. Initial experience with DCD LTx is promising and, in combination with exÂ vivo lung perfusion systems, seems a valuable opportunity to expand the lung donor pool.
Hemodynamic response to exercise and head-up tilt of patients implanted with a rotary blood pump: a computational modeling study. - Artificial organs
The present study investigates the response of implantable rotary blood pump (IRBP)-assisted patients to exercise and head-up tilt (HUT), as well as the effect of alterations in the model parameter values on this response, using validated numerical models. Furthermore, we comparatively evaluate the performance of a number of previously proposed physiologically responsive controllers, including constant speed, constant flow pulsatility index (PI), constant average pressure difference between the aorta and the left atrium, constant average differential pump pressure, constant ratio between mean pump flow and pump flow pulsatility (ratioP I or linear Starling-like control), as well as constant left atrial pressure ( P l a Â¯ ) control, with regard to their ability to increase cardiac output during exercise while maintaining circulatory stability upon HUT. Although native cardiac output increases automatically during exercise, increasing pump speed was able to further improve total cardiac output and reduce elevated filling pressures. At the same time, reduced venous return associated with upright posture was not shown to induce left ventricular (LV) suction. Although P l a Â¯ control outperformed other control modes in its ability to increase cardiac output during exercise, it caused a fall in the mean arterial pressure upon HUT, which may cause postural hypotension or patient discomfort. To the contrary, maintaining constant average pressure difference between the aorta and the left atrium demonstrated superior performance in both exercise and HUT scenarios. Due to their strong dependence on the pump operating point, PI and ratioPI control performed poorly during exercise and HUT. Our simulation results also highlighted the importance of the baroreflex mechanism in determining the response of the IRBP-assisted patients to exercise and postural changes, where desensitized reflex response attenuated the percentage increase in cardiac output during exercise and substantially reduced the arterial pressure upon HUT.Copyright Â© 2014 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
Too high for transplantation? Single-center analysis of the lung allocation score. - The Annals of thoracic surgery
Recent studies using United Network for Organ Sharing data suggest that lung transplantation in patients with high lung allocation scores (LAS) may lead to organ and resource wastage. Therefore, to determine whether a LAS cutoff value should be considered, we evaluated the relation of LAS to waitlist and posttransplant mortality in our center to determine if it could identify patients for whom listing for transplantation may be futile.From May 1, 2005 to July 1, 2010, 537 adults were listed and 426 underwent primary lung transplantation at our institution. Endpoints were mortality before and after lung transplantation. The relationships of LAS at listing to waitlist mortality and of pretransplant LAS to posttransplant mortality were both analyzed by multiphase hazard function methodology.Higher LAS was strongly associated with waitlist mortality (p<0.0001), with the highest quartile (LAS ranging from 47 to 95) experiencing 75% mortality within a year of listing. Although early (p=0.05), but not late (p=0.4), posttransplant survival was associated with higher LAS at transplantation, once other clinical characteristics predictive of early mortality were accounted for, neither waitlist nor pretransplant LAS was independently related to posttransplant mortality (p=0.12).Higher LAS strongly predicts higher mortality on the lung transplantation waitlist, underscoring the value of LAS in prioritizing patients with the highest scores for transplantation. Early posttransplant mortality is modestly higher with higher pretransplant LAS, but the data of our center do not suggest a value above which transplantation should be denied as futile. This suggests that donor organs and resources are not being wasted.Copyright Â© 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesoph - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Preoperative chemoradiotherapy improves local control in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Distant failure remains common, however, suggesting potential benefit from additional chemotherapy. This phase II study investigated the addition of induction chemotherapy to surgery and adjuvant chemoradiotherapy.Patients with cT3-4 or N1 or M1a (American Joint Committee on Cancer 6th edition) adenocarcinoma of the esophagus and GEJ were eligible. Induction chemotherapy, with epirubicin 50 mg/m/d, oxaliplatin 130 mg/m/d, and fluorouracil 200 mg/m/d continuous infusion for 3 weeks, was given every 21 days for three courses, followed by surgery. Adjuvant chemoradiotherapy consisted of 50 to 55 Gy at 1.8 to 2.0 Gy/d and two courses of cisplatin (20 mg/m/d) and fluorouracil (1000 mg/m/d) during weeks 1 and 4 of radiotherapy.Between February 2008 and January 2012, 60 evaluable patients enrolled. Resection was accomplished in 54 patients (90%) and adjuvant chemoradiotherapy in 48 (80%) patients. Toxicity included unplanned hospitalization in 18% of patients during induction chemotherapy and 19% of patients during adjuvant chemoradiotherapy. There was one chemotherapy-related and two postoperative deaths. With a median follow-up of 43 months, the projected 3-year locoregional control is 88%, distant metastatic control 46%, relapse-free survival 41%, and overall survival 47%. Symptomatic response to chemotherapy and the percentage of remaining viable tumor at surgery proved the strongest predictors of survival and distant control.Chemotherapy, surgery, and adjuvant chemoradiotherapy are feasible and produce outcomes similar to other multimodality treatment schedules in locoregionally advanced adenocarcinoma of the esophagus and GEJ. Symptomatic response and less residual tumor at surgery were associated with improved outcomes.
Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. - Journal of pediatric gastroenterology and nutrition
The aim of the study was to prospectively evaluate clinical and mucosal responses to the specific carbohydrate diet (SCD) in children with Crohn disease (CD).Eligible patients with active CD (Pediatric Crohn's Disease Activity Index [PCDAI] â‰¥ 15) underwent a patency capsule and, if passed intact, capsule endoscopy (CE) was performed. Patients taking SCD were monitored for 52 weeks while maintaining all prescribed medications. Demographic, dietary, and clinical information, PCDAI, Harvey-Bradshaw Index (HBI), and Lewis score (LS) were collected at 0, 12, and 52 weeks. CEs were evaluated by an experienced reader blinded to patient clinical information and timing.Sixteen patients were screened; 10 enrolled; and 9 completed the initial 12-week trial-receiving 85% of estimated caloric needs before, and 101% on the SCD. HB significantly decreased from 3.3 Â± 2.0 to 0.6 Â± 1.3 (P = 0.007) as did PCDAI (21.1 Â± 5.9 to 7.8 Â± 7.1, P = 0.011). LS declined significantly from 2153 Â± 732 to 960â€Š Â± 433 (P = 0.012). Seven patients continued the SCD up to 52 weeks; HB (0.1 Â± 0.4) and PCDAI (5.4 Â± 5.5) remained improved (P = 0.016 and 0.027 compared to baseline), with mean LS at 1046 Â± 372 and 2 patients showed sustained mucosal healing.Clinical and mucosal improvements were seen in children with CD, who used SCD for 12 and 52 weeks. In addition, CE can monitor mucosal improvement in treatment trials for pediatric CD. Further studies are critically needed to understand the mechanisms underlying SCD's effectiveness in children with CD.
Robotic surgery for primary hyperparathyroidism. - Surgical endoscopy
Open cervical parathyroidectomy is the standard of care for the treatment of primary hyperparathyroidism (PHP). However, in patients with a history of keloid or hypertrophic scar formation, the cosmetic result may sometimes be unsatisfactory. Furthermore, in the presence of mediastinal glands, a more morbid approach is sometimes necessary, involving a sternal split or thoracotomy. Robotic parathyroidectomy, either transaxillary or transthoracic, could be an alternative in both settings.Between 2008 and 2013, 14 patients with PHP and a well-localized single adenoma underwent robotic transaxillary cervical (TAC) (nÂ =Â 8) or transthoracic mediastinal (TTM) (nÂ =Â 6) parathyroidectomy at an academic tertiary medical center and their outcomes were analyzed.All 14 operations were completed successfully as planned. For TAC and TTM parathyroidectomies, mean operative time was 184 and 168 min, respectively. With the exception of one TTM patient, intraoperative PTH determination indicated a >50Â % drop in all patients 10Â min after excision and no patients presented with recurrent disease on follow-up. Average length of hospital stay was 1Â day after TAC parathyroidectomy and 2.2Â days after TTM. On a visual analog pain scale (0-10), average pain scores after TAC were 6/10 on postoperative day 1 and 1/10 on day 14, compared to 7.7/10 and 1.5/10, respectively, after TTM. Complications included development of seroma in 1 patient in the TAC group and pericardial and pleural effusion in 1 patient in the TTM cohort.This initial study shows that robotic TAC and TTM parathyroidectomy are feasible in selected PHP patients with preoperatively well-localized disease. Although the TAC approach offers a potential cosmetic benefit in patients with a history of keloid or hypertrophic scar formation, a more generalized use cannot be recommended based on current evidence. The robotic TTM approach presents a minimally invasive alternative to resections previously performed through thoracotomy and sternotomy.
Health information technology adoption in New Zealand optometric practices. - Clinical & experimental optometry : journal of the Australian Optometrical Association
Health information technology (HIT) has the potential to fundamentally change the practice of optometry and the relationship between optometrists and patients and to improve clinical outcomes. This paper aims to provide data on how health information technology is currently being used in New Zealand optometric practices. Also this paper aims to explore the potential benefits and barriers to the future adoption of health information technology in New Zealand.One hundred and six New Zealand optometrists were surveyed about their current use of health information technology and about potential benefits and barriers. In addition, 12 semi-structured interviews were carried out with leaders of health information technology in New Zealand optometry. The areas of interest were the current and intended use of HIT, the potential benefits of and barriers to using HIT in optometric offices and the level of investment in health information technology.Nearly all optometrists (98.7 per cent) in New Zealand use computers in their practices and 93.4 per cent of them use a computer in their consulting room. The most commonly used clinical assessment technology in optometric practices in New Zealand was automated perimeter (97.1 per cent), followed by a digital fundus/retinal camera (82.6 per cent) and automated lensometer (62.9 per cent). The pachymeter is the technology that most respondents intended to purchase in the next one to five years (42.6 per cent), followed by a scanning laser ophthalmoscope (36.8 per cent) and corneal topographer (32.9 per cent). The main benefits of using health information technology in optometric practices were improving patient perceptions of â€˜state of the artâ€™ practice and providing patients with information and digital images to explain the results of assessment. Barriers to the adoption of HIT included the need for frequent technology upgrades, cost, lack of time for implementation, and training.New Zealand optometrists are using HIT broadly in their practices and expect HIT use to increase over time.
Starling-like flow control of a left ventricular assist device: in vitro validation. - Artificial organs
The application of rotary left ventricular (LV) assist devices (LVADs) is expanding from bridge to transplant, to destination and bridge to recovery therapy. Conventional constant speed LVAD controllers do not regulate flow according to preload, and can cause over/underpumping, leading to harmful ventricular suction or pulmonary edema, respectively. We implemented a novel adaptive controller which maintains a linear relationship between mean flow and flow pulsatility to imitate native Starling-like flow regulation which requires only the measurement of VAD flow. In vitro controller evaluation was conducted and the flow sensitivity was compared during simulations of postural change, pulmonary hypertension, and the transition from sleep to wake. The Starling-like controller's flow sensitivity to preload was measured as 0.39 L/min/mm Hg, 10 times greater than constant speed control (0.04 L/min/mm Hg). Constant speed control induced LV suction after sudden simulated pulmonary hypertension, whereas Starling-like control reduced mean flow from 4.14 to 3.58 L/min, maintaining safe support. From simulated sleep to wake, Starling-like control increased flow 2.93 to 4.11 L/min as a response to the increased residual LV pulsatility. The proposed controller has the potential to better match device outflow to patient demand in comparison with conventional constant speed control.Â© 2013 Wiley Periodicals, Inc. and International Center for Artificial Organs and Transplantation.
Esophagopulmonary fistula and left lung abscess after transoral incisionless fundoplication. - The Annals of thoracic surgery
Endoscopic treatment of gastroesophageal reflux disease (GERD) is emerging as an alternative to open, laparoscopic, or robotic antireflux surgical procedures. Early transoral devices failed because of poor efficacy and serious adverse events. In recent trials the EsophyX device has demonstrated acceptable safety and a reasonable efficacy profile. We present the case of a woman who experienced a distal esophageal perforation and esophagopulmonary fistula after treatment for GERD with the EsophyX device. Although considered minimally invasive, endoscopic procedures for GERD treatment can have significant deleterious consequences, and early recognition of these complications is vital to limit associated morbidity.Copyright Â© 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Comparative study of bronchial artery revascularization in lung transplantation. - The Journal of thoracic and cardiovascular surgery
Restoring dual blood supply to transplanted lungs by bronchial artery revascularization (BAR) remains controversial. We compared outcomes after lung transplantation performed with and without BAR.From December 2007 to July 2010, 283 patients underwent transplantation; 187 were 18 years or older, without previous or concomitant cardiac surgery. Of these patients, 27 underwent BAR in a pilot study to test success, safety, effectiveness, and teachability. A propensity score was generated to match BAR patients and 54 routine non-BAR patients. Follow-up was 1.3 Â± 0.68 years.BAR was angiographically successful in 26 (96%) of 27 patients. BAR and non-BAR patients had similar skin-to-skin time (PÂ =Â .07) and postoperative hospital stays (PÂ =Â .2), but more reoperations for bleeding (PÂ =Â .002). Tracheostomy was performed in 9 (33%) of 27 BAR and 10 (19%) of 54 non-BAR patients (PÂ =Â .2, log-rank). One BAR (3.7%) and 4 non-BAR (7.4%) patients required extracorporeal membrane oxygenation (PÂ =Â .7). Airway ischemia was observed in 1 BAR (3.7%) versus 12 non-BAR (22%) patients (PÂ =Â .03); anastomotic intervention was required in no BAR versus 8 non-BAR (15%) patients (PÂ =Â .04). Hospital mortality was 1 of 27 versus 2 of 54 (PÂ =Â .9). BAR patients had lower early biopsy tissue rejection grades (PÂ =Â .008) and fewer pulmonary (PÂ <Â .04) and bloodstream (PÂ <Â .02) infections. Forced 1-second expiratory volume was similar (P > .2); 3 BAR versus 9 non-BAR patients developed bronchiolitis obliterans syndrome (BOS) (PÂ =Â .14, log-rank). During follow-up, 4 BAR and 8 non-BAR patients died (PÂ =Â .6, log-rank).BAR is safe, with comparable early outcomes. Benefits of BAR include reduced airway ischemia and complications, lower biopsy tissue grades, fewer infections, and delay of BOS. A multicenter study is needed to establish these benefits.Copyright Â© 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Map & Directions
855 Montgomery St Fort Worth, TX 76107
855 Montgomery St
855 Montgomery St Unt Health- Patient Care Center, 6Th Floor